K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.27 CAD 0.76%
Market Cap: 531.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one GUD stock under the Base Case scenario is 4.97 CAD. Compared to the current market price of 5.27 CAD, Knight Therapeutics Inc is Overvalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GUD Relative Value
Base Case
4.97 CAD
Overvaluation 6%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
95
vs Industry
57
Median 3Y
1.7
Median 5Y
2.4
Industry
2.5
Forward
1.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-27.1
Median 5Y
-18.5
Industry
21.8
Forward
-104.3
More Details
10.1
P/OCF
P/OCF
Price to OCF
10.1
vs History
69
vs Industry
37
Median 3Y
15
Median 5Y
14.9
Industry
16.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
19
Median 3Y
16.1
Median 5Y
-3.2
Industry
23.8
More Details
0.7
P/B
P/B
Price to Book Value
0.7
vs History
85
vs Industry
68
Median 3Y
0.7
Median 5Y
0.8
Industry
2.1
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
95
vs Industry
64
Median 3Y
1.4
Median 5Y
1.7
Industry
2.7
Forward
1.1
More Details
2.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.3
vs History
98
vs Industry
62
Median 3Y
3
Median 5Y
3.5
Industry
5.2
More Details
7.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.6
vs History
77
vs Industry
38
Median 3Y
9.3
Median 5Y
9.7
Industry
13.5
Forward
6.7
More Details
297.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
297.9
vs History
3
vs Industry
3
Median 3Y
-33.3
Median 5Y
-27.8
Industry
16.8
Forward
35.6
More Details
7.4
EV/OCF
EV/OCF
Enterprise Value to OCF
7.4
vs History
71
vs Industry
42
Median 3Y
11.4
Median 5Y
10.8
Industry
15.2
More Details
19
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
19
vs History
36
vs Industry
31
Median 3Y
17.4
Median 5Y
9.3
Industry
19.3
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
76
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9
More Details

Multiples Across Competitors

GUD Competitors Multiples
Knight Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Knight Therapeutics Inc
TSX:GUD
528.1m CAD 1.5 -17.3 7.6 297.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.4 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average P/S: 382 942.1
1.5
23%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average P/E: 32.3
Negative Multiple: -17.3 		N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average EV/EBITDA: 414.3
7.6
13%
0.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average EV/EBIT: 1 839.9
297.9
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Summary
GUD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GUD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GUD stock valuation using valuation multiples.
Wall Street Estimates
GUD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GUD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.